Efeito da suplementação de Mio-Inositol sobre os parâmetros glicêmicos e de resistência à insulina em mulheres com síndrome dos ovários policístico: uma revisão sistemática

Abstract

Introduction: Insulin resistance, which is characterized by a reduced sensitivity to the action of insulin in tissues, is an important component in the development of Polycystic Ovary Syndrome (PCOS). In this case, myo-inositol supplementation seems to have a promising effect on insulin resistance. Objective: In this sense, this study aimed to evaluate the scientific evidence on the effect of myo-inositol supplementation and its isomer on glycemic parameters and insulin resistance in women with PCOS. Methods: Searches were carried out in Pubmed, Web of Science, Scopus and Google Search databases, in the last 10 years, using the keywords: myo-inositol, polycistic ovarian syndrome, PCOS and D-chiro inositol. The methodological quality and risk of bias of clinical trials were assessed using the tool proposed by Cochrane for randomized trials (RoB2). Results: So, 17 articles (12 clinical trials and 5 meta-analyses) are included in the review. As for clinical trials, MI supplementation was evaluated in isolated forms (n=8), combined with the isomer (n=3) and combined with another compound (n=1). The dose ranged from 500 mg to 4 g/day and the supplementation time from 12 weeks to 6 months. In the case of MI alone, the dose of 4 g/day proved to be more effective in reducing overall glycemic parameters and insulin resistance, when supplemented for a period equal to or greater than 3 months. The combination of MI with its isomer was more effective in improving the studied parameters when in the physiological ratio of 40:1. The effects of the association of MI with other compounds are still inconclusive. Conclusion: Thus, the use of MI (alone) seems to be a good therapeutic strategy in the treatment of PCOS, mainly because it is a safe option, with low cost and without side effects, when compared to other forms of treatment.